If successful, the DIABIL-2 trial will have profound impacts for the management of patients with newly diagnosed T1D, their families and EU economy:

Impact on T1D management:
Ultra-low dose as a safe treatment aimed at halting autoimmune β-cell destruction could enable patients to achieve optimal glycaemic control without recurrent hypoglycaemia. Moreover, the efficacy of IL-2 at halting autoimmune β-cell destruction in newly diagnosed T1D could lead to further studies investigating its potential in prevention of T1D. 

Impact on Global health issues:
More than 20 million people in Europe suffer from T1D.  The costs of treating and managing this disease and its complications are approximately 2 billion € annually.  Progress in autoimmune and inflammatory diseases management: Noteworthy, any clinical success ultra-low dose in T1D could lead to its clinical development in other autoimmune diseases, including Multiple Sclerosis or Rheumatoid Arthritis, that have a significant public health burden. A confirmation of the global anti-inflammatory effect of IL-2 already observed in HCV-related vasculitis patients will pave the way for studying IL-2 in other inflammatory diseases. 

Impact on Child Health:
This disease has a major impact on children and adolescents since it interferes with all aspects of life and is often disrupting for the whole family and social structure around the child. We firmly believe that by building on a strong model of T1D pathogenesis, supported by world-class research, we are proposing a rational approach towards intervening in T1D. We bring the hope of intervention in this disease.


Economic impact:
The use of IL-2 in T1D and other autoimmune diseases has been patented by the DIABIL-2 coordinating public institution AP-HP, and the patent is currently licensed to ILTOO-biotech, a small company also a partner in this project. Demonstration of efficacy in this T1D trial should be a milestone in developing novel indications for IL-2. Europe will have a chance to become a leader in this field, which targets a very large market, and likewise this project should contribute to increasing employment in the pharmaceutical sector in the EU.